<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>Wiley-Blackwell</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24843762</article-id><article-id pub-id-type="pmc">4023585</article-id><article-id pub-id-type="doi">10.1111/jdi.12135</article-id><article-id pub-id-type="publisher-id">JDI12135</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparison of three &#x003b1;&#x02010;glucosidase inhibitors for glycemic control and bodyweight reduction in <styled-content style="fixed-case">J</styled-content>apanese patients with obese type&#x000a0;2 diabetes</article-title><alt-title alt-title-type="left-running-head">Sugihara <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12135-cr-0001" contrib-type="author"><name><surname>Sugihara</surname><given-names>Hitoshi</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0002" contrib-type="author"><name><surname>Nagao</surname><given-names>Mototsugu</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0003" contrib-type="author"><name><surname>Harada</surname><given-names>Taro</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0004" contrib-type="author"><name><surname>Nakajima</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0005" contrib-type="author"><name><surname>Tanimura&#x02010;Inagaki</surname><given-names>Kyoko</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0006" contrib-type="author"><name><surname>Okajima</surname><given-names>Fumitaka</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0007" contrib-type="author"><name><surname>Tamura</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib><contrib id="jdi12135-cr-0008" contrib-type="author"><name><surname>Inazawa</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0002"><sup>2</sup></xref></contrib><contrib id="jdi12135-cr-0009" contrib-type="author"><name><surname>Otonari</surname><given-names>Takatoshi</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0003"><sup>3</sup></xref></contrib><contrib id="jdi12135-cr-0010" contrib-type="author"><name><surname>Kawakami</surname><given-names>Masanobu</given-names></name><xref ref-type="aff" rid="jdi12135-aff-0004"><sup>4</sup></xref></contrib><contrib id="jdi12135-cr-0011" contrib-type="author"><name><surname>Oikawa</surname><given-names>Shinichi</given-names></name><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="jdi12135-aff-0001"><sup>1</sup></xref></contrib></contrib-group><aff id="jdi12135-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Metabolism</named-content><named-content content-type="organisation-division">Department of Medicine</named-content><institution>Nippon Medical School</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="jdi12135-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Metabolism</named-content><named-content content-type="organisation-division">Department of Medicine</named-content><institution>Kashiwa City Hospital</institution><named-content content-type="city">Kashiwa</named-content><country country="JP">Japan</country></aff><aff id="jdi12135-aff-0003"><label><sup>3</sup></label><institution>Otonari Medical Clinic</institution><named-content content-type="city">Fukuoka</named-content><country country="JP">Japan</country></aff><aff id="jdi12135-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Medicine</named-content><institution>Saitama Medical Center</institution><institution>Jichi Medical University</institution><named-content content-type="city">Saitama</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Corresponding author. Shinichi Oikawa Tel.: +81&#x02010;3&#x02010;3822&#x02010;2131 Fax: +81&#x02010;3&#x02010;5802&#x02010;8153 E&#x02010;mail address: <email>shinichi@nms.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>3</month><year>2014</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/jdi.2014.5.issue-2</issue-id><fpage>206</fpage><lpage>212</lpage><history><date date-type="received"><day>25</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>20</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2014 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd</copyright-statement><copyright-statement content-type="article-copyright">&#x000a9; 2013 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:jdi-5-206.pdf"/><abstract abstract-type="main" id="jdi12135-abs-0001"><title>Abstract</title><sec id="jdi12135-sec-0001"><title>Aims/Introduction</title><p>&#x003b1;&#x02010;Glucosidase inhibitors (&#x003b1;<styled-content style="fixed-case">GI</styled-content>s) are widely used for the primary treatment of type&#x000a0;2 diabetes. We compared the clinical effects of three &#x003b1;<styled-content style="fixed-case">GI</styled-content>s (miglitol, acarbose and voglibose) in patients with obese type&#x000a0;2 diabetes.</p></sec><sec id="jdi12135-sec-0002"><title>Materials and Methods</title><p>Japanese patients (<italic>n</italic>&#x000a0;=&#x000a0;81) with obese type&#x000a0;2 diabetes (body mass index [<styled-content style="fixed-case">BMI</styled-content>] &#x02265;25&#x000a0;kg/m<sup>2</sup>) were enrolled in this multicenter, open&#x02010;label study. The participants were randomized into the miglitol (<italic>n</italic>&#x000a0;=&#x000a0;18), acarbose (<italic>n</italic>&#x000a0;=&#x000a0;22), voglibose (<italic>n</italic>&#x000a0;=&#x000a0;19) or control (<italic>n</italic>&#x000a0;=&#x000a0;22) groups. Glycemic control (fasting blood glucose and glycated hemoglobin [HbA1c]), bodyweight, <styled-content style="fixed-case">BMI</styled-content>, serum insulin, serum lipids (low&#x02010;density lipoprotein and high&#x02010;density lipoprotein cholesterol, and triacylglycerols) and adipocytokines (leptin and adiponectin) were evaluated every 4&#x000a0;weeks for 12&#x000a0;weeks.</p></sec><sec id="jdi12135-sec-0003"><title>Results</title><p>In the miglitol group, <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c was improved significantly from the baseline at all points. The changes in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c at 8 and 12&#x000a0;weeks from baseline were greater in the miglitol group than the control group. The voglibose group showed significant improvements in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c at 12&#x000a0;weeks. Bodyweight and <styled-content style="fixed-case">BMI</styled-content> were decreased significantly in the miglitol group. In addition, significant correlations were observed between the decrements in <styled-content style="fixed-case">H</styled-content>b<styled-content style="fixed-case">A</styled-content>1c and bodyweights over 12&#x000a0;weeks in the miglitol (<italic>r</italic>&#x000a0;=&#x000a0;0.759, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and voglibose groups (<italic>r</italic>&#x000a0;=&#x000a0;0.667, <italic>P</italic>&#x000a0;=&#x000a0;0.002). Serum lipid and adipocytokine levels were not altered in any groups.</p></sec><sec id="jdi12135-sec-0004"><title>Conclusions</title><p>&#x003b1;<styled-content style="fixed-case">GI</styled-content>s, especially miglitol, can effectively control blood glucose and bodyweight in obese type&#x000a0;2 diabetes. This study was registered with <styled-content style="fixed-case">UMIN</styled-content> (no. <styled-content style="fixed-case">UMIN</styled-content>000006465).</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12135-kwd-0001">Bodyweight</kwd><kwd id="jdi12135-kwd-0002">Type 2 diabetes mellitus</kwd><kwd id="jdi12135-kwd-0003">&#x003b1;&#x02010;Glucoseidase inhibitor</kwd></kwd-group><funding-group><award-group><funding-source>Sanwa Kagaku Kenkyusho Co., Ltd.</funding-source></award-group></funding-group><counts><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12135</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2014</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLM version:4.0.3 mode:remove_FC converted:23.03.2014</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation"><mixed-citation publication-type="self-citation" id="jdi12135-cit-1001"><source>J Diabetes Invest</source><year>2014</year>; 5: 206&#x02013;212</mixed-citation></p></notes></front><body><sec sec-type="intro" id="jdi12135-sec-0005"><title>Introduction</title><p>Type&#x000a0;2 diabetes is a well&#x02010;known risk factor for cardiovascular disease. Several experimental results suggest that postprandial hyperglycemic spikes contribute to the pathophysiology of diabetic cardiovascular complications. The suppression of postprandial hyperglycemia is therefore a promising approach for preventing cardiovascular disease in type&#x000a0;2 diabetes<xref rid="jdi12135-bib-0001" ref-type="ref">1</xref>.</p><p>&#x003b1;&#x02010;Glucosidase inhibitors (&#x003b1;GIs) are widely used for the primary treatment of type&#x000a0;2 diabetes. They inhibit maltase, sucrase and other disaccharide hydrolases (i.e., suppress the degradation of disaccharides to monosaccharides) in the brush border membrane of the small intestine<xref rid="jdi12135-bib-0002" ref-type="ref">2</xref>. Therefore, &#x003b1;GIs can improve postprandial hyperglycemia by delaying carbohydrate absorption. The Study to Prevent Non&#x02010;Insulin&#x02010;Dependent Diabetes Mellitus trial<xref rid="jdi12135-bib-0003" ref-type="ref">3</xref> showed that treatment with an &#x003b1;GI, acarbose, is associated with a significant risk reduction in cardiovascular events in patients with impaired glucose tolerance or type&#x000a0;2 diabetes. Subsequently, much attention has been focused on &#x003b1;GIs as therapeutic agents for type&#x000a0;2 diabetes and its complications.</p><p>Weight gain in type&#x000a0;2 diabetes not only worsens diabetic control, but also increases the risk of diabetes&#x02010;associated cardiovascular complications<xref rid="jdi12135-bib-0004" ref-type="ref">4</xref>. However, glycemic control with insulin or certain oral hypoglycemic agents (insulin secretagogues and thiazolidinediones) promotes weight gain<xref rid="jdi12135-bib-0005" ref-type="ref">5</xref>. In contrast, biguanides and incretin&#x02010;related drugs (glucagon&#x02010;like peptide&#x000a0;1 [GLP&#x02010;1] analogs and dipeptidyl peptidase&#x000a0;4 inhibitors) have beneficial effects on bodyweight. Meanwhile, the effects of &#x003b1;GIs on bodyweight control remain unclear. Whereas some studies suggest that &#x003b1;GIs can reduce bodyweight in type&#x000a0;2 diabetes<xref rid="jdi12135-bib-0003 jdi12135-bib-0006" ref-type="ref">3</xref>, a meta&#x02010;analysis of randomized controlled trials with acarbose showed that it has minor effects for lowering bodyweight<xref rid="jdi12135-bib-0007" ref-type="ref">7</xref>.</p><p>Three &#x003b1;GIs are now clinically available in Japan: acarbose, miglitol and voglibose. However, to our knowledge, there have been no reports comparing these drugs head&#x02010;to&#x02010;head. In the present study, we evaluated the effects of these three &#x003b1;GIs on glycemic control, weight management and other clinical measures in the treatment of Japanese patients with obese type&#x000a0;2 diabetes.</p></sec><sec sec-type="materials|methods" id="jdi12135-sec-0006"><title>Materials and Methods</title><p>The present study was a multicenter (Nippon Medical School Hospital; Saitama Medical Center, Jichi Medical University; Hachijo Municipal Hospital; Kashiwa City Hospital; and Otonari Medical Clinic), open&#x02010;label, randomized study. The protocol was approved by each institutional ethics review board, and all participants were enrolled after being informed of the clinical trial and providing written consent.</p><sec id="jdi12135-sec-0007"><title>Participants</title><p>The study included 81 outpatients (38 men and 43 women) with obese type&#x000a0;2 diabetes (aged &#x02265;40&#x000a0;years; glycated hemoglobin [HbA1c] 6.4&#x02013;8.4%; body mass index [BMI] &#x02265;25&#x000a0;kg/m<sup>2</sup>). HbA1c was measured by the latex agglutination method and expressed as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%)<xref rid="jdi12135-bib-0008 jdi12135-bib-0009" ref-type="ref">8</xref>. Patients who had received insulin therapy or &#x003b1;GI medication, or had a serious hepatic, renal, or cardiac disease were excluded.</p></sec><sec id="jdi12135-sec-0008"><title>Study Design</title><p>After the informed consent was obtained, an application form was sent to an external registration center by facsimile. Approved participants were allocated to one of four treatment groups using a random number list for miglitol (150&#x000a0;mg/day), acarbose (300&#x000a0;mg/day), voglibose (0.9&#x000a0;mg/day) and control (no additive medication). The dose of miglitol was not the maximum dose approved in Japan (225&#x000a0;mg/day), whereas acarbose and voglibose were used at maximum doses, because these doses are generally used in practice. All patients underwent a 12&#x02010;week therapy with the assigned regimen, and were instructed to maintain their usual diet and medications over the study period.</p><p>Anthropometric measurements and blood sample tests were carried out after an overnight fast at baseline, and 4, 8 and 12&#x000a0;weeks after the treatment. The primary end&#x02010;points were HbA1c, bodyweight and BMI, as well as their changes from baseline after drug treatment. The secondary end&#x02010;points included other glycemic parameters (fasting plasma glucose [FPG] and serum insulin), serum lipids (total cholesterol [TC], low&#x02010;density lipoprotein cholesterol [LDL&#x02010;C], high&#x02010;density lipoprotein cholesterol [HDL&#x02010;C] and triacylglycerols [TG]) and adipocytokines (leptin and adiponectin). All patients completed questionnaires about their digestive symptoms (borborygmus, abdominal distension, flatulence and fecal condition), appetite and drug compliance every 4&#x000a0;weeks.</p></sec><sec id="jdi12135-sec-0009"><title>Statistical Analyses</title><p>The clinical characteristics of patients were analyzed by the &#x003c7;<sup>2</sup>&#x02010;test or one&#x02010;way analysis of variance (<sc>anova</sc>). The changes over the study period were analyzed by two&#x02010;way <sc>anova</sc> with Bonferroni correction. Intergroup differences were analyzed by two&#x02010;way repeated&#x02010;measures <sc>anova</sc> with Bonferroni correction. The questionnaire results were analyzed by the Friedman test with Bonferroni correction. The level of statistical significance was set at <italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05. Associations between changes in HbA1c and bodyweight were evaluated by Pearson's correlation coefficient analysis. All statistical analyses were carried out using SPSS for Windows, Japanese version 16.0 (SPSS Institute Inc., Tokyo, Japan).</p></sec></sec><sec sec-type="results" id="jdi12135-sec-0010"><title>Results</title><p>Of the 81 enrolled patients, 78 had sufficient baseline and follow&#x02010;up data to evaluate the primary end&#x02010;points (Figure&#x000a0;<xref rid="jdi12135-fig-0001" ref-type="fig">1</xref>). Two patients in the control group and one in the acarbose group with insufficient data were excluded from the statistical analysis. The baseline characteristics of the study participants are shown in Table&#x000a0;<xref rid="jdi12135-tbl-0001" ref-type="table-wrap">1</xref>. There were no significant differences in the clinical characteristics among the four groups.</p><table-wrap id="jdi12135-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline characteristics of the participants</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Control</th><th align="left" valign="bottom" rowspan="1" colspan="1">Miglitol</th><th align="left" valign="bottom" rowspan="1" colspan="1">Acarbose</th><th align="left" valign="bottom" rowspan="1" colspan="1">Voglibose</th><th align="left" valign="bottom" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of patients</td><td align="left" char="." rowspan="1" colspan="1">22</td><td align="left" char="." rowspan="1" colspan="1">18</td><td align="left" char="." rowspan="1" colspan="1">22</td><td align="left" char="." rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male/female</td><td align="left" char="." rowspan="1" colspan="1">7/15</td><td align="left" char="." rowspan="1" colspan="1">10/8</td><td align="left" char="." rowspan="1" colspan="1">13/9</td><td align="left" char="." rowspan="1" colspan="1">8/11</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" char="." rowspan="1" colspan="1">66.6&#x000a0;&#x000b1;&#x000a0;13.0</td><td align="left" char="." rowspan="1" colspan="1">66.3&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="left" char="." rowspan="1" colspan="1">61.8&#x000a0;&#x000b1;&#x000a0;13.7</td><td align="left" char="." rowspan="1" colspan="1">66.7&#x000a0;&#x000b1;&#x000a0;12.3</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" char="." rowspan="1" colspan="1">155&#x000a0;&#x000b1;&#x000a0;9.5</td><td align="left" char="." rowspan="1" colspan="1">156&#x000a0;&#x000b1;&#x000a0;9.8</td><td align="left" char="." rowspan="1" colspan="1">159&#x000a0;&#x000b1;&#x000a0;10.3</td><td align="left" char="." rowspan="1" colspan="1">157&#x000a0;&#x000b1;&#x000a0;8.4</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Bodyweight (kg)</td><td align="left" char="." rowspan="1" colspan="1">69.6&#x000a0;&#x000b1;&#x000a0;14.3</td><td align="left" char="." rowspan="1" colspan="1">67.8&#x000a0;&#x000b1;&#x000a0;11.2</td><td align="left" char="." rowspan="1" colspan="1">72.7&#x000a0;&#x000b1;&#x000a0;11.5</td><td align="left" char="." rowspan="1" colspan="1">70.8&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" char="." rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left" char="." rowspan="1" colspan="1">28.2&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left" char="." rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="left" char="." rowspan="1" colspan="1">28.9&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c, NGSP (%)</td><td align="left" char="." rowspan="1" colspan="1">7.26&#x000a0;&#x000b1;&#x000a0;0.79</td><td align="left" char="." rowspan="1" colspan="1">7.08&#x000a0;&#x000b1;&#x000a0;0.61</td><td align="left" char="." rowspan="1" colspan="1">7.11&#x000a0;&#x000b1;&#x000a0;0.66</td><td align="left" char="." rowspan="1" colspan="1">7.14&#x000a0;&#x000b1;&#x000a0;0.59</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mmol/L)</td><td align="left" char="." rowspan="1" colspan="1">7.55&#x000a0;&#x000b1;&#x000a0;1.34</td><td align="left" char="." rowspan="1" colspan="1">7.10&#x000a0;&#x000b1;&#x000a0;1.05</td><td align="left" char="." rowspan="1" colspan="1">7.71&#x000a0;&#x000b1;&#x000a0;1.63</td><td align="left" char="." rowspan="1" colspan="1">7.00&#x000a0;&#x000b1;&#x000a0;1.32</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="left" char="." rowspan="1" colspan="1">5.00&#x000a0;&#x000b1;&#x000a0;0.74</td><td align="left" char="." rowspan="1" colspan="1">5.07&#x000a0;&#x000b1;&#x000a0;0.79</td><td align="left" char="." rowspan="1" colspan="1">5.21&#x000a0;&#x000b1;&#x000a0;1.26</td><td align="left" char="." rowspan="1" colspan="1">4.75&#x000a0;&#x000b1;&#x000a0;0.72</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="left" char="." rowspan="1" colspan="1">3.06&#x000a0;&#x000b1;&#x000a0;0.86</td><td align="left" char="." rowspan="1" colspan="1">3.08&#x000a0;&#x000b1;&#x000a0;0.78</td><td align="left" char="." rowspan="1" colspan="1">3.28&#x000a0;&#x000b1;&#x000a0;0.84</td><td align="left" char="." rowspan="1" colspan="1">2.67&#x000a0;&#x000b1;&#x000a0;0.50</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td align="left" char="." rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.29</td><td align="left" char="." rowspan="1" colspan="1">1.37&#x000a0;&#x000b1;&#x000a0;0.25</td><td align="left" char="." rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.36</td><td align="left" char="." rowspan="1" colspan="1">1.23&#x000a0;&#x000b1;&#x000a0;0.30</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td align="left" char="." rowspan="1" colspan="1">1.57&#x000a0;&#x000b1;&#x000a0;0.75</td><td align="left" char="." rowspan="1" colspan="1">1.42&#x000a0;&#x000b1;&#x000a0;0.44</td><td align="left" char="." rowspan="1" colspan="1">1.57&#x000a0;&#x000b1;&#x000a0;0.99</td><td align="left" char="." rowspan="1" colspan="1">1.41&#x000a0;&#x000b1;&#x000a0;0.63</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" colspan="6" rowspan="1">Concomitant medications, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Oral hypoglycemic agents</td><td align="left" char="." rowspan="1" colspan="1">19 (86.4)</td><td align="left" char="." rowspan="1" colspan="1">12 (66.7)</td><td align="left" char="." rowspan="1" colspan="1">15 (68.2)</td><td align="left" char="." rowspan="1" colspan="1">16 (84.2)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Sulfonylurea</td><td align="left" char="." rowspan="1" colspan="1">6 (27.3)</td><td align="left" char="." rowspan="1" colspan="1">8 (44.4)</td><td align="left" char="." rowspan="1" colspan="1">8 (36.4)</td><td align="left" char="." rowspan="1" colspan="1">8 (42.1)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Glinide</td><td align="left" char="." rowspan="1" colspan="1">8 (36.4)</td><td align="left" char="." rowspan="1" colspan="1">2 (11.1)</td><td align="left" char="." rowspan="1" colspan="1">4 (18.2)</td><td align="left" char="." rowspan="1" colspan="1">3 (15.8)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">DPP&#x02010;4 inhibitor</td><td align="left" char="." rowspan="1" colspan="1">0 (0.0)</td><td align="left" char="." rowspan="1" colspan="1">0 (0.0)</td><td align="left" char="." rowspan="1" colspan="1">0 (0.0)</td><td align="left" char="." rowspan="1" colspan="1">1 (5.3)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Thiazolidinedione</td><td align="left" char="." rowspan="1" colspan="1">3 (13.6)</td><td align="left" char="." rowspan="1" colspan="1">3 (16.7)</td><td align="left" char="." rowspan="1" colspan="1">1 (4.6)</td><td align="left" char="." rowspan="1" colspan="1">3 (15.8)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Metformin</td><td align="left" char="." rowspan="1" colspan="1">11 (50.0)</td><td align="left" char="." rowspan="1" colspan="1">5 (27.8)</td><td align="left" char="." rowspan="1" colspan="1">11 (50.0)</td><td align="left" char="." rowspan="1" colspan="1">8 (42.1)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypotensive agents</td><td align="left" char="." rowspan="1" colspan="1">18 (81.8)</td><td align="left" char="." rowspan="1" colspan="1">14 (77.8)</td><td align="left" char="." rowspan="1" colspan="1">11 (50.0)</td><td align="left" char="." rowspan="1" colspan="1">15 (79.0)</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypolipidemic agents</td><td align="left" char="." rowspan="1" colspan="1">11 (50.0)</td><td align="left" char="." rowspan="1" colspan="1">4 (22.2)</td><td align="left" char="." rowspan="1" colspan="1">8 (36.4)</td><td align="left" char="." rowspan="1" colspan="1">10 (52.6)</td><td align="left" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="jdi12135-note-0001"><p>Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high&#x02010;density lipoprotein; LDL, low&#x02010;density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; TG, triacylglycerols; DPP&#x02010;4, dipeptidyl peptidase&#x000a0;4. NS, not significant (<italic>P&#x000a0;</italic>&#x02265;&#x000a0;0.05).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdi12135-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study.</p></caption><graphic xlink:href="jdi-5-206-g1"><alt-text>image</alt-text></graphic></fig><sec id="jdi12135-sec-0011"><title>Primary Endpoints</title><p>Table&#x000a0;<xref rid="jdi12135-tbl-0002" ref-type="table-wrap">2</xref> shows HbA1c, bodyweight, and BMI in the four groups. In the control group, HbA1c increased significantly from baseline at 12&#x000a0;weeks of treatment. In the miglitol group, HbA1c decreased significantly from baseline at 4&#x000a0;weeks, and the decreased HbA1c level was kept over the study period. In the voglibose group, a significant decrease was observed in HbA1c after 12&#x000a0;weeks of treatment. HbA1c did not change significantly in the acarbose group over the study period (Table&#x000a0;<xref rid="jdi12135-tbl-0002" ref-type="table-wrap">2</xref>). In addition, the changes in HbA1c from baseline (&#x00394;HbA1c) in the miglitol group were greater than those in the control group at 8 and 12&#x000a0;weeks of treatment (Figure&#x000a0;<xref rid="jdi12135-fig-0002" ref-type="fig">2</xref>a).</p><table-wrap id="jdi12135-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><title>Changes in glycated hemoglobin, bodyweight and body mass index during the study period (primary end&#x02010;points)</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="left" valign="bottom" rowspan="1" colspan="1">4 weeks</th><th align="left" valign="bottom" rowspan="1" colspan="1">8&#x000a0;weeks</th><th align="left" valign="bottom" rowspan="1" colspan="1">12&#x000a0;weeks</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">HbA1c (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.24&#x000a0;&#x000b1;&#x000a0;0.81</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.21&#x000a0;&#x000b1;&#x000a0;0.69</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.34&#x000a0;&#x000b1;&#x000a0;0.78</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.47&#x000a0;&#x000b1;&#x000a0;0.78<xref ref-type="fn" rid="jdi12135-note-0002">*</xref></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.08&#x000a0;&#x000b1;&#x000a0;0.61</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.89&#x000a0;&#x000b1;&#x000a0;0.64<xref ref-type="fn" rid="jdi12135-note-0002">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.77&#x000a0;&#x000b1;&#x000a0;0.59<xref ref-type="fn" rid="jdi12135-note-0002">***</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.73&#x000a0;&#x000b1;&#x000a0;0.58<xref ref-type="fn" rid="jdi12135-note-0002">***</xref>
<xref ref-type="fn" rid="jdi12135-note-0002">&#x02020;</xref></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.12&#x000a0;&#x000b1;&#x000a0;0.68</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.04&#x000a0;&#x000b1;&#x000a0;0.61</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.04&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.06&#x000a0;&#x000b1;&#x000a0;0.72</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.14&#x000a0;&#x000b1;&#x000a0;0.59</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.03&#x000a0;&#x000b1;&#x000a0;0.57</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.97&#x000a0;&#x000b1;&#x000a0;0.70</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.94&#x000a0;&#x000b1;&#x000a0;0.80<xref ref-type="fn" rid="jdi12135-note-0002">*</xref></td></tr><tr><td align="left" colspan="5" rowspan="1">Bodyweight (kg)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.9&#x000a0;&#x000b1;&#x000a0;14.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.6&#x000a0;&#x000b1;&#x000a0;14.8</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.8&#x000a0;&#x000b1;&#x000a0;14.9</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.6&#x000a0;&#x000b1;&#x000a0;15.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.0&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">68.5&#x000a0;&#x000b1;&#x000a0;11.1<xref ref-type="fn" rid="jdi12135-note-0002">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">68.2&#x000a0;&#x000b1;&#x000a0;11.4<xref ref-type="fn" rid="jdi12135-note-0002">***</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">67.8&#x000a0;&#x000b1;&#x000a0;11.2<xref ref-type="fn" rid="jdi12135-note-0002">***</xref></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">72.1&#x000a0;&#x000b1;&#x000a0;11.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">72.0&#x000a0;&#x000b1;&#x000a0;11.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">72.2&#x000a0;&#x000b1;&#x000a0;11.5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">71.9&#x000a0;&#x000b1;&#x000a0;12.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">70.8&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">70.5&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">70.4&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">70.2&#x000a0;&#x000b1;&#x000a0;11.0</td></tr><tr><td align="left" colspan="5" rowspan="1">BMI (kg/m<sup>2</sup>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.5&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.5&#x000a0;&#x000b1;&#x000a0;3.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.2&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.0&#x000a0;&#x000b1;&#x000a0;3.1<xref ref-type="fn" rid="jdi12135-note-0002">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">27.8&#x000a0;&#x000b1;&#x000a0;3.2<xref ref-type="fn" rid="jdi12135-note-0002">***</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">27.7&#x000a0;&#x000b1;&#x000a0;3.1<xref ref-type="fn" rid="jdi12135-note-0002">***</xref></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;2.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.9&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.8&#x000a0;&#x000b1;&#x000a0;5.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.8&#x000a0;&#x000b1;&#x000a0;5.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">28.6&#x000a0;&#x000b1;&#x000a0;4.9</td></tr></tbody></table><table-wrap-foot><fn id="jdi12135-note-0002"><p>Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation. BMI, body mass index; HbA1c, glycated hemoglobin. *<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05, ***<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.001 vs baseline. &#x02020;<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05 vs control group.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="jdi12135-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in (a) glycated hemoglobin (&#x00394;HbA1c), (b) bodyweight (&#x00394;<styled-content style="fixed-case">BW</styled-content>) and (c) body mass index (&#x00394;<styled-content style="fixed-case">BMI</styled-content>) from baseline. Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;standard error of the mean. *<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05, ***<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.001 vs baseline. &#x02020;<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05, &#x02020;&#x02020;<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.01 vs control group. &#x025cb;, Control; &#x02666;, miglitol; &#x025b2;, acarbose; &#x025a0;, voglibose.</p></caption><graphic xlink:href="jdi-5-206-g2"><alt-text>image</alt-text></graphic></fig><p>The bodyweight of the miglitol group decreased significantly from baseline at 4, 8 and 12&#x000a0;weeks of treatment, whereas no significant bodyweight changes were observed in any other groups over the study period (Table&#x000a0;<xref rid="jdi12135-tbl-0002" ref-type="table-wrap">2</xref> and Figure&#x000a0;<xref rid="jdi12135-fig-0002" ref-type="fig">2</xref>b). Consequently, BMI was decreased from baseline only in the miglitol group at 4, 8 and 12&#x000a0;weeks (Table&#x000a0;<xref rid="jdi12135-tbl-0002" ref-type="table-wrap">2</xref> and Figure&#x000a0;<xref rid="jdi12135-fig-0002" ref-type="fig">2</xref>c). However, no significant differences were observed in the changes from baseline in bodyweight (&#x00394;BW) or BMI (&#x00394;BMI) among the four groups (Figure&#x000a0;<xref rid="jdi12135-fig-0002" ref-type="fig">2</xref>b,c).</p><p>There were significant correlations between &#x00394;HbA1c and &#x00394;BW at 12&#x000a0;weeks in the miglitol (<italic>r</italic>&#x000a0;=&#x000a0;0.759, <italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.001) and voglibose (<italic>r</italic>&#x000a0;=&#x000a0;0.667, <italic>P&#x000a0;</italic>=&#x000a0;0.002) groups (Figure&#x000a0;<xref rid="jdi12135-fig-0003" ref-type="fig">3</xref>b,d). A similar correlation was observed between &#x00394;HbA1c and &#x00394;BW at 12&#x000a0;weeks&#x000a0;in all participants (<italic>r</italic>&#x000a0;=&#x000a0;0.476, <italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.001; Figure&#x000a0;<xref rid="jdi12135-fig-0003" ref-type="fig">3</xref>e). No significant correlations were observed in the control and acarbose groups (Figure&#x000a0;<xref rid="jdi12135-fig-0003" ref-type="fig">3</xref>a,c).</p><fig fig-type="Figure" xml:lang="en" id="jdi12135-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Correlations between changes in glycated hemoglobin (&#x00394;HbA1c) and bodyweight (&#x00394;<styled-content style="fixed-case">BW</styled-content>) over 12&#x000a0;weeks. (a) Control, (b) miglitol, (c) acarbose, (d) voglibose group and (e) total participants. &#x025cb;, Control; &#x02666;, miglitol; &#x025b2;, acarbose; &#x025a0;, voglibose.</p></caption><graphic xlink:href="jdi-5-206-g3"><alt-text>image</alt-text></graphic></fig></sec><sec id="jdi12135-sec-0012"><title>Secondary End&#x02010;points</title><p>Over the study period, neither FPG nor serum insulin was changed significantly in any groups. In addition, no significant changes were observed in serum lipid profiles or adipocytokines at any time&#x02010;point in any groups (Table&#x000a0;<xref rid="jdi12135-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="jdi12135-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><title>Changes in fasting plasma glucose, serum insulin, serum lipids and adipocytokines during the study period (secondary end&#x02010;points)</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="left" valign="bottom" rowspan="1" colspan="1">4&#x000a0;weeks</th><th align="left" valign="bottom" rowspan="1" colspan="1">8&#x000a0;weeks</th><th align="left" valign="bottom" rowspan="1" colspan="1">12&#x000a0;weeks</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">FPG (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.43&#x000a0;&#x000b1;&#x000a0;1.47</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.47&#x000a0;&#x000b1;&#x000a0;1.04</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.60&#x000a0;&#x000b1;&#x000a0;1.29</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.50&#x000a0;&#x000b1;&#x000a0;1.37</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.22&#x000a0;&#x000b1;&#x000a0;1.05</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.12&#x000a0;&#x000b1;&#x000a0;0.96</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.16&#x000a0;&#x000b1;&#x000a0;1.10</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.11&#x000a0;&#x000b1;&#x000a0;1.46</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.41&#x000a0;&#x000b1;&#x000a0;1.59</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.39&#x000a0;&#x000b1;&#x000a0;1.13</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.36&#x000a0;&#x000b1;&#x000a0;1.51</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.10&#x000a0;&#x000b1;&#x000a0;1.00</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.65&#x000a0;&#x000b1;&#x000a0;1.24</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.94&#x000a0;&#x000b1;&#x000a0;1.32</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.80&#x000a0;&#x000b1;&#x000a0;1.40</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.67&#x000a0;&#x000b1;&#x000a0;1.54</td></tr><tr><td align="left" colspan="5" rowspan="1">Serum insulin (pmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">80.2&#x000a0;&#x000b1;&#x000a0;47.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">87.3&#x000a0;&#x000b1;&#x000a0;75.6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">87.7&#x000a0;&#x000b1;&#x000a0;66.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">70.2&#x000a0;&#x000b1;&#x000a0;33.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">63.4&#x000a0;&#x000b1;&#x000a0;49.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">60.8&#x000a0;&#x000b1;&#x000a0;45.5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">54.8&#x000a0;&#x000b1;&#x000a0;41.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">61.6&#x000a0;&#x000b1;&#x000a0;49.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">80.9&#x000a0;&#x000b1;&#x000a0;54.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">101&#x000a0;&#x000b1;&#x000a0;58.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">161&#x000a0;&#x000b1;&#x000a0;191</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">68.0&#x000a0;&#x000b1;&#x000a0;38.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">75.3&#x000a0;&#x000b1;&#x000a0;38.6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">96.7&#x000a0;&#x000b1;&#x000a0;86.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">69.4&#x000a0;&#x000b1;&#x000a0;36.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">79.3&#x000a0;&#x000b1;&#x000a0;41.2</td></tr><tr><td align="left" colspan="5" rowspan="1">Total cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.78&#x000a0;&#x000b1;&#x000a0;0.61</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.96&#x000a0;&#x000b1;&#x000a0;0.61</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.94&#x000a0;&#x000b1;&#x000a0;0.65</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.01&#x000a0;&#x000b1;&#x000a0;0.55</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.12&#x000a0;&#x000b1;&#x000a0;0.90</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.23&#x000a0;&#x000b1;&#x000a0;1.03</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.62&#x000a0;&#x000b1;&#x000a0;1.21</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.43&#x000a0;&#x000b1;&#x000a0;1.29</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.30&#x000a0;&#x000b1;&#x000a0;1.44</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.53&#x000a0;&#x000b1;&#x000a0;1.23</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.48&#x000a0;&#x000b1;&#x000a0;1.39</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5.42&#x000a0;&#x000b1;&#x000a0;1.76</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.88&#x000a0;&#x000b1;&#x000a0;0.66</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.79&#x000a0;&#x000b1;&#x000a0;0.49</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.58&#x000a0;&#x000b1;&#x000a0;0.69</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4.81&#x000a0;&#x000b1;&#x000a0;0.57</td></tr><tr><td align="left" colspan="5" rowspan="1">LDL cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.00&#x000a0;&#x000b1;&#x000a0;0.96</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.94&#x000a0;&#x000b1;&#x000a0;0.81</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.86&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.00&#x000a0;&#x000b1;&#x000a0;0.75</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.04&#x000a0;&#x000b1;&#x000a0;0.85</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.15&#x000a0;&#x000b1;&#x000a0;0.82</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.08&#x000a0;&#x000b1;&#x000a0;0.87</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.87&#x000a0;&#x000b1;&#x000a0;0.79</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.24&#x000a0;&#x000b1;&#x000a0;0.73</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.23&#x000a0;&#x000b1;&#x000a0;0.73</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.32&#x000a0;&#x000b1;&#x000a0;0.91</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">3.07&#x000a0;&#x000b1;&#x000a0;1.12</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.64&#x000a0;&#x000b1;&#x000a0;0.56</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.67&#x000a0;&#x000b1;&#x000a0;0.66</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.82&#x000a0;&#x000b1;&#x000a0;0.54</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2.80&#x000a0;&#x000b1;&#x000a0;0.59</td></tr><tr><td align="left" colspan="5" rowspan="1">HDL cholesterol (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.37&#x000a0;&#x000b1;&#x000a0;0.28</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.32&#x000a0;&#x000b1;&#x000a0;0.27</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.35&#x000a0;&#x000b1;&#x000a0;0.27</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.31&#x000a0;&#x000b1;&#x000a0;0.28</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.28</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.40&#x000a0;&#x000b1;&#x000a0;0.26</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.28</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.38&#x000a0;&#x000b1;&#x000a0;0.31</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.36&#x000a0;&#x000b1;&#x000a0;0.26</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.22</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.35&#x000a0;&#x000b1;&#x000a0;0.30</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.33&#x000a0;&#x000b1;&#x000a0;0.18</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.27&#x000a0;&#x000b1;&#x000a0;0.29</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.23&#x000a0;&#x000b1;&#x000a0;0.31</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.23&#x000a0;&#x000b1;&#x000a0;0.24</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.22&#x000a0;&#x000b1;&#x000a0;0.25</td></tr><tr><td align="left" colspan="5" rowspan="1">TG (mmol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.52&#x000a0;&#x000b1;&#x000a0;0.69</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.71&#x000a0;&#x000b1;&#x000a0;1.27</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.63&#x000a0;&#x000b1;&#x000a0;0.81</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.68&#x000a0;&#x000b1;&#x000a0;0.81</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.56&#x000a0;&#x000b1;&#x000a0;0.37</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.48&#x000a0;&#x000b1;&#x000a0;0.69</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.34&#x000a0;&#x000b1;&#x000a0;0.50</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.56&#x000a0;&#x000b1;&#x000a0;1.20</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.66&#x000a0;&#x000b1;&#x000a0;1.14</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.48&#x000a0;&#x000b1;&#x000a0;1.02</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.95&#x000a0;&#x000b1;&#x000a0;1.85</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.59&#x000a0;&#x000b1;&#x000a0;0.94</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.68</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.62&#x000a0;&#x000b1;&#x000a0;1.45</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.35&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.37&#x000a0;&#x000b1;&#x000a0;0.37</td></tr><tr><td align="left" colspan="5" rowspan="1">Adiponectin (&#x003bc;g/mL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9.98&#x000a0;&#x000b1;&#x000a0;6.06</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.1&#x000a0;&#x000b1;&#x000a0;7.59</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.1&#x000a0;&#x000b1;&#x000a0;6.53</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9.97&#x000a0;&#x000b1;&#x000a0;5.87</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9.96&#x000a0;&#x000b1;&#x000a0;4.05</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9.88&#x000a0;&#x000b1;&#x000a0;4.84</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.3&#x000a0;&#x000b1;&#x000a0;5.81</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.3&#x000a0;&#x000b1;&#x000a0;5.80</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.91&#x000a0;&#x000b1;&#x000a0;3.78</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.26&#x000a0;&#x000b1;&#x000a0;2.89</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.66&#x000a0;&#x000b1;&#x000a0;2.94</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.27&#x000a0;&#x000b1;&#x000a0;2.03</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">13.0&#x000a0;&#x000b1;&#x000a0;13.6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.2&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.9&#x000a0;&#x000b1;&#x000a0;15.8</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.3&#x000a0;&#x000b1;&#x000a0;11.5</td></tr><tr><td align="left" colspan="5" rowspan="1">Leptin (ng/mL)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Control</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.3&#x000a0;&#x000b1;&#x000a0;6.42</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.1&#x000a0;&#x000b1;&#x000a0;8.88</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.6&#x000a0;&#x000b1;&#x000a0;6.63</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.8&#x000a0;&#x000b1;&#x000a0;7.80</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Miglitol</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.98&#x000a0;&#x000b1;&#x000a0;3.95</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.73&#x000a0;&#x000b1;&#x000a0;3.56</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.08&#x000a0;&#x000b1;&#x000a0;4.87</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.41&#x000a0;&#x000b1;&#x000a0;4.17</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acarbose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.7&#x000a0;&#x000b1;&#x000a0;8.35</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.0&#x000a0;&#x000b1;&#x000a0;7.35</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.5&#x000a0;&#x000b1;&#x000a0;8.49</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.0&#x000a0;&#x000b1;&#x000a0;7.41</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Voglibose</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.1&#x000a0;&#x000b1;&#x000a0;7.68</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.1&#x000a0;&#x000b1;&#x000a0;7.02</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.1&#x000a0;&#x000b1;&#x000a0;7.91</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.7&#x000a0;&#x000b1;&#x000a0;8.42</td></tr></tbody></table><table-wrap-foot><fn id="jdi12135-note-0003"><p>Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation. FPG, fasting plasma glucose; HDL, high&#x02010;density lipoprotein; LDL, low&#x02010;density lipoprotein; TG, triacylglycerols.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jdi12135-sec-0013"><title>Questionnaire</title><p>The questionnaire data on digestive symptoms showed that the participants in the three &#x003b1;GI&#x02010;treated groups experienced some digestive symptoms. Participants in the acarbose group in particular reported increased incidences of persistent borborygmus, abdominal distension and flatulence (Table S1). No distinct differences were observed among the groups with respect to drug compliance or appetite.</p></sec></sec><sec sec-type="discussion" id="jdi12135-sec-0014"><title>Discussion</title><p>In the present study, we evaluated the effects of three &#x003b1;GIs on glycemic control and bodyweight reduction in Japanese patients with obese type&#x000a0;2 diabetes. Miglitol and voglibose lowered HbA1c, whereas only miglitol reduced bodyweight and BMI.</p><p>&#x003b1;GIs retard carbohydrate digestion and absorption, and thus reduce postprandial hyperglycemia. Among the three &#x003b1;GIs, miglitol differs from acarbose and voglibose with respect to pharmacokinetics. After oral administration, acarbose and voglibose are practically not absorbed<xref rid="jdi12135-bib-0010 jdi12135-bib-0011" ref-type="ref">10</xref>. In contrast, miglitol presents at a high concentration in the upper small intestine and is subsequently absorbed<xref rid="jdi12135-bib-0012" ref-type="ref">12</xref>. Such differences in pharmacokinetics could contribute to the superior therapeutic benefit of miglitol; that is, it can suppress the postprandial blood glucose elevation most effectively. Indeed, recent studies with continuous glucose monitoring showed that miglitol strongly reduces postprandial blood glucose levels in type&#x000a0;2 diabetes<xref rid="jdi12135-bib-0013 jdi12135-bib-0014" ref-type="ref">13</xref>. Although there were no concurrent changes in fasting plasma glucose or insulin levels, adequate suppression of postprandial hyperglycemia could contribute to the rapid and persistent reduction of HbA1c in the miglitol group. Meanwhile, in the present study, HbA1c did not show a significant decrease in the acarbose group. Most of the previous intervention studies with acarbose were carried out for much longer durations, and reported that acarbose treatment significantly reduced HbA1c<xref rid="jdi12135-bib-0007" ref-type="ref">7</xref>. Therefore, the relatively short study period (12&#x000a0;weeks) might obscure the blood glucose&#x02010;lowering effect of acarbose.</p><p>Intensive diabetic therapies with insulin and its secretagogues increase the risk of weight gain in type&#x000a0;2 diabetes<xref rid="jdi12135-bib-0015 jdi12135-bib-0016" ref-type="ref">15</xref>. Weight gain and obesity could induce insulin resistance and increase the risk of cardiovascular diseases in such patients. In the present study, a weight&#x02010;lowering effect was observed only in the miglitol group. The effects of miglitol on incretins might be one of the reasons for this result. Recent studies suggest that miglitol enhances the release of GLP&#x02010;1 whilst it suppresses the release of glucose&#x02010;dependent insulinotropic polypeptide (GIP) by increasing glucose absorption from the lower small intestine<xref rid="jdi12135-bib-0017 jdi12135-bib-0018" ref-type="ref">17</xref>. Indeed, elevated GLP&#x02010;1 contributes to appetite control by inhibiting gastrointestinal motility<xref rid="jdi12135-bib-0019" ref-type="ref">19</xref> and inducing satiety<xref rid="jdi12135-bib-0020" ref-type="ref">20</xref> through the central nervous system. In fact, Arakawa <italic>et&#x000a0;al</italic>.<xref rid="jdi12135-bib-0021" ref-type="ref">21</xref> report that miglitol affects postprandial GLP&#x02010;1 secretion more strongly than acarbose in patients with visceral obesity, and several reports suggest that miglitol increases GLP&#x02010;1 and decreases GIP to greater extents than voglibose after a single<xref rid="jdi12135-bib-0022" ref-type="ref">22</xref> or long&#x02010;term<xref rid="jdi12135-bib-0006" ref-type="ref">6</xref> administration in type&#x000a0;2 diabetes. Further analysis for the modulation of postprandial incretin levels with &#x003b1;GIs could explain the differences in the weight&#x02010;lowering effects among &#x003b1;GIs.</p><p>We did not find any changes in fasting plasma lipid profiles in the present study. However, a meta&#x02010;analysis of acarbose showed a small tendency towards decreased fasting TG levels<xref rid="jdi12135-bib-0007" ref-type="ref">7</xref>. In addition, some studies showed that postprandial TG decreased significantly in accordance with decreased insulin levels with acute<xref rid="jdi12135-bib-0023 jdi12135-bib-0024" ref-type="ref">23</xref> or long&#x02010;term<xref rid="jdi12135-bib-0024" ref-type="ref">24</xref> acarbose treatment in type&#x000a0;2 diabetes. These data suggest that the improvement of insulin resistance by &#x003b1;GIs might suppress postprandial TG elevation. Hence, postprandial insulin and TG levels should be assessed to further understand the lipid&#x02010;lowering effect of each &#x003b1;GI.</p><p>After the 12&#x02010;week &#x003b1;GI treatment, a significant decrease in HbA1c was observed in the miglitol and voglibose groups, but not in the acarbose group. In addition, a significant correlation was observed between &#x00394;HbA1c and &#x00394;BW in the miglitol and voglibose groups. Thus, the improved glycemic control with these &#x003b1;GIs might be partly due to weight reduction. A few studies suggest that acarbose and miglitol increase plasma adiponectin levels<xref rid="jdi12135-bib-0025 jdi12135-bib-0026" ref-type="ref">25</xref>. Although reductions in bodyweight and body fat mass by &#x003b1;GIs are speculated to modulate adipocytokine levels, adiponectin and leptin levels did not change in any groups of the present study. Other pathways, such as those involving incretins, could contribute to both the better glycemic control and bodyweight reduction by &#x003b1;GIs. Miglitol<xref rid="jdi12135-bib-0017" ref-type="ref">17</xref> and voglibose<xref rid="jdi12135-bib-0027" ref-type="ref">27</xref> have been reported to increase postprandial incretin levels in patients with type&#x000a0;2 diabetes, whereas acarbose has not<xref rid="jdi12135-bib-0028" ref-type="ref">28</xref>, in placebo&#x02010;controlled studies. Further research into the underlying mechanisms of the different effects on glycemic control and bodyweight among &#x003b1;GIs is necessary for better understanding of the characteristics of these drugs.</p><p>The present study had several limitations. First, this study was an open&#x02010;label study with a small sample size, though the participants were randomized and a control group was included. Second, we did not evaluate postprandial levels of plasma glucose, insulin and incretins. These postprandial measures would provide direct information on the effects of &#x003b1;GI. Third, we did not select the maximum dose permitted in Japan in the miglitol group. If the maximum dose was selected, it could be preferable to the present dose for both blood glucose and bodyweight control in the miglitol group. However, as the dose of &#x003b1;GI is increased, the side&#x02010;effects such as abdominal symptoms might be likely to occur. It remains to be elucidated whether the maximum dose of miglitol would have superior efficacy with good tolerability. Fourth, we investigated only patients with obese type&#x000a0;2 diabetes. Whether similar effects of miglitol are observed in other types of diabetes or individuals with impaired glucose tolerance is of particular interest. Further investigation is required to better understand these characteristics of each &#x003b1;GI.</p><p>In conclusion, the present findings show that miglitol and voglibose lowered HbA1c in patients with obese type&#x000a0;2 diabetes. In addition, miglitol reduced bodyweight within a short period (4&#x000a0;weeks of treatment). These results suggest that miglitol is a preferable agent for improving glycemic control with promoting bodyweight reduction. Further studies on the characteristics of each &#x003b1;GI could provide better treatment options, not only for blood glucose control with bodyweight management, but also for preventing complications in type&#x000a0;2 diabetes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><caption><p><bold>Table S1 |</bold> Questionnaire survey data.</p></caption><media xlink:href="jdi-5-206-s4.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jdi12135-sec-0015"><title>Acknowledgements</title><p>This study was supported by Sanwa Kagaku Kenkyusho Co., Ltd. There is no conflict of interest for all the authors listed.</p></ack><ref-list content-type="cited-references" id="jdi12135-bibl-0001"><title>References</title><ref id="jdi12135-bib-0001"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Gallwitz</surname>
<given-names>B</given-names></string-name>. <article-title>Implications of Postprandial Glucose and Weight Control in People With Type&#x000a0;2 Diabetes: understanding and implementing the International Diabetes Federation guidelines</article-title>. <source>Diabetes Care</source><year>2009</year>; <volume>32</volume>: <fpage>S322</fpage>&#x02013;<lpage>S325</lpage><pub-id pub-id-type="pmid">19875573</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0002"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Lebovitz</surname>
<given-names>HE</given-names></string-name>. <article-title>&#x003b1;&#x02010;Glucosidase inhibitors</article-title>. <source>Endocrinol Metab Clin North Am</source><year>1997</year>; <volume>26</volume>: <fpage>539</fpage>&#x02013;<lpage>551</lpage><pub-id pub-id-type="pmid">9314014</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0003"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Hanefeld</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cagatay</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Petrowitsch</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Acarbose reduces the risk for myocardial infarction in type&#x000a0;2 diabetic patients: meta&#x02010;analysis of seven long&#x02010;term studies</article-title>. <source>Eur Heart J</source><year>2004</year>; <volume>25</volume>: <fpage>10</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="pmid">14683737</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0004"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Kendall</surname>
<given-names>CWC</given-names></string-name>, <string-name><surname>Jenkins</surname>
<given-names>DJA</given-names></string-name>. <article-title>Importance of weight management in type&#x000a0;2 diabetes: review with meta&#x02010;analysis of clinical studies</article-title>. <source>J Am Coll Nutr</source><year>2003</year>; <volume>22</volume>: <fpage>331</fpage>&#x02013;<lpage>339</lpage><pub-id pub-id-type="pmid">14559925</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0005"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Phung</surname>
<given-names>OJ</given-names></string-name>, <string-name><surname>Scholle</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Talwar</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type&#x000a0;2 diabetes</article-title>. <source>JAMA</source><year>2010</year>; <volume>303</volume>: <fpage>1410</fpage>&#x02013;<lpage>1418</lpage><pub-id pub-id-type="pmid">20388897</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0006"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Narita</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Yokoyama</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yamashita</surname>
<given-names>R</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Comparisons of the effects of 12&#x02010;week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type&#x000a0;2 diabetic patients</article-title>. <source>Diabetes Obes Metab</source><year>2012</year>; <volume>14</volume>: <fpage>283</fpage>&#x02013;<lpage>287</lpage><pub-id pub-id-type="pmid">22051162</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0007"><label>7</label><mixed-citation publication-type="journal"><string-name>
<surname>van de Laar</surname>
<given-names>FA</given-names></string-name>, <string-name><surname>Lucassen</surname>
<given-names>PL</given-names></string-name>, <string-name><surname>Akkermans</surname>
<given-names>RP</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>&#x003b1;&#x02010;glucosidase inhibitors for patients with type&#x000a0;2 diabetes: results from a Cochrane systematic review and meta&#x02010;analysis</article-title>. <source>Diabetes Care</source><year>2005</year>; <volume>28</volume>: <fpage>154</fpage>&#x02013;<lpage>163</lpage><pub-id pub-id-type="pmid">15616251</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0008"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Seino</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Nanjo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tajima</surname>
<given-names>N</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Report of the committee on the classification and diagnostic criteria of diabetes mellitus</article-title>. <source>J Diabetes Invest</source><year>2010</year>; <volume>1</volume>: <fpage>212</fpage>&#x02013;<lpage>228</lpage></mixed-citation></ref><ref id="jdi12135-bib-0009"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Kashiwagi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kasuga</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Araki</surname>
<given-names>E</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values</article-title>. <source>J Diabetes Invest</source><year>2012</year>; <volume>3</volume>: <fpage>39</fpage>&#x02013;<lpage>40</lpage></mixed-citation></ref><ref id="jdi12135-bib-0010"><label>10</label><mixed-citation publication-type="book"><string-name><surname>Puetter</surname>
<given-names>J</given-names></string-name>. <source>Studies on the Pharmacokinetics of Acarbose in Humans. Enzyme Inhibitors</source>. <publisher-name>Verlag Chimie</publisher-name>, <publisher-loc>Weinheim</publisher-loc>, <year>1980</year>; <fpage>139</fpage>&#x02013;<lpage>151</lpage></mixed-citation></ref><ref id="jdi12135-bib-0011"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Hiraga</surname>
<given-names>K</given-names></string-name>. <article-title>Pharmacokinetics of AO&#x02010;128 and its Influences on Carbohydrate Metabolism &#x02013; a study in healthy volunteers</article-title>. <source>Clin Rep</source><year>1992</year>; <volume>26</volume>: <fpage>283</fpage>&#x02013;<lpage>294</lpage> (Japanese).</mixed-citation></ref><ref id="jdi12135-bib-0012"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Ahr</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Boberg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brendel</surname>
<given-names>E</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man</article-title>. <source>Arzneimittelforschung</source><year>1997</year>; <volume>47</volume>: <fpage>734</fpage>&#x02013;<lpage>745</lpage><pub-id pub-id-type="pmid">9239452</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0013"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Kishimoto</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Noda</surname>
<given-names>M</given-names></string-name>. <article-title>A pilot study of the efficacy of miglitol and sitagliptin for type&#x000a0;2diabetes with a continuous glucose monitoring system and incretin&#x02010;related markers</article-title>. <source>Cardiovasc Diabetol</source><year>2011</year>; <volume>10</volume>: <fpage>115</fpage><pub-id pub-id-type="pmid">22189184</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0014"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Tsujino</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nishimura</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Taki</surname>
<given-names>K</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Comparing the efficacy of &#x003b1;&#x02010;glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study&#x02010;the MAJOR study</article-title>. <source>Diabetes Technol Ther</source><year>2011</year>; <volume>13</volume>: <fpage>303</fpage>&#x02013;<lpage>308</lpage><pub-id pub-id-type="pmid">21291335</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0015"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>DeFronzo</surname>
<given-names>RA</given-names></string-name>. <article-title>Pharmacologic therapy for type&#x000a0;2 diabetes mellitus</article-title>. <source>Ann Intern Med</source><year>1999</year>; <volume>131</volume>: <fpage>281</fpage>&#x02013;<lpage>303</lpage><pub-id pub-id-type="pmid">10454950</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0016"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Turner</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cull</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Holman</surname>
<given-names>R</given-names></string-name>. <article-title>United Kingdom Prospective Diabetes Study 17: a 9&#x02010;year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non&#x02010;insulin&#x02010;dependent diabetes mellitus</article-title>. <source>Ann Intern Med</source><year>1996</year>; <volume>124</volume>: <fpage>136</fpage>&#x02013;<lpage>145</lpage><pub-id pub-id-type="pmid">8554206</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0017"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Patrick</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wishart</surname>
<given-names>J</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>The effects of miglitol on glucagon&#x02010;like peptide&#x02010;1 secretion and appetite sensations in obese type 2 diabetics</article-title>. <source>Diabetes Obes Metab</source><year>2002</year>; <volume>4</volume>: <fpage>329</fpage>&#x02013;<lpage>335</lpage><pub-id pub-id-type="pmid">12190996</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0018"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Narita</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Katsuura</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Miglitol induces prolonged and enhanced glucagon&#x02010;like peptide&#x02010;1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type&#x000a0;2 diabetic patients</article-title>. <source>Diabet Med</source><year>2009</year>; <volume>26</volume>: <fpage>187</fpage>&#x02013;<lpage>188</lpage><pub-id pub-id-type="pmid">19236625</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0019"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Delgado&#x02010;Aros</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>D&#x02010;Y</given-names></string-name>, <string-name><surname>Burton</surname>
<given-names>DD</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effect of GLP&#x02010;1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans</article-title>. <source>Am J Physiol</source><year>2002</year>; <volume>282</volume>: <fpage>G424</fpage>&#x02013;<lpage>G431</lpage></mixed-citation></ref><ref id="jdi12135-bib-0020"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Gutzwiller</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>G&#x000f6;ke</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Drewe</surname>
<given-names>J</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Glucagon&#x02010;like peptide&#x02010;1: a potent regulator of food intake in humans</article-title>. <source>Gut</source><year>1999</year>; <volume>44</volume>: <fpage>81</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="pmid">9862830</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0021"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Arakawa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ebato</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mita</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon&#x02010;like peptide 1 secretion in viscerally obese subjects</article-title>. <source>Metabolism</source><year>2008</year>; <volume>57</volume>: <fpage>1299</fpage>&#x02013;<lpage>1306</lpage><pub-id pub-id-type="pmid">18702958</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0022"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Hiki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shimada</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kiyanagi</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Single administration of &#x003b1;&#x02010;Glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease</article-title>. <source>Circ J</source><year>2010</year>; <volume>74</volume>: <fpage>1471</fpage>&#x02013;<lpage>1478</lpage><pub-id pub-id-type="pmid">20519875</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0023"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Kado</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Murakami</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Aoki</surname>
<given-names>A</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effect of acarbose on postprandial lipid metabolism in type&#x000a0;2 diabetes mellitus</article-title>. <source>Diabetes Res Clin Pract</source><year>1998</year>; <volume>41</volume>: <fpage>49</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="pmid">9768372</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0024"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Ogawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Takeuchi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ito</surname>
<given-names>S</given-names></string-name>. <article-title>Acarbose lowers serum triglyceride and postprandial chylomicron levels in type&#x000a0;2 diabetes</article-title>. <source>Diabetes Obes Metab</source><year>2004</year>; <volume>6</volume>: <fpage>384</fpage>&#x02013;<lpage>390</lpage><pub-id pub-id-type="pmid">15287932</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0025"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Ochiai</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ooka</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Shida</surname>
<given-names>C</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Acarbose treatment increases serum total adiponectin levels in patients with type&#x000a0;2 diabetes</article-title>. <source>Endocr J</source><year>2008</year>; <volume>55</volume>: <fpage>549</fpage>&#x02013;<lpage>556</lpage><pub-id pub-id-type="pmid">18480556</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0026"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Yokoyama</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kannno</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ishimura</surname>
<given-names>I</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type&#x000a0;2 diabetes mellitus</article-title>. <source>Metabolism</source><year>2007</year>; <volume>56</volume>: <fpage>1458</fpage>&#x02013;<lpage>1463</lpage><pub-id pub-id-type="pmid">17950094</pub-id></mixed-citation></ref><ref id="jdi12135-bib-0027"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>G&#x000f6;ke</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Fuder</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wieckhorst</surname>
<given-names>G</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Voglibose (AO&#x02010;128) is an efficient &#x003b1;&#x02010;glucosidase inhibitor and mobilizes the endogenous GLP&#x02010;1 reserve</article-title>. <source>Digestion</source><year>1995</year>; <volume>56</volume>: <fpage>439</fpage>&#x02013;<lpage>501</lpage></mixed-citation></ref><ref id="jdi12135-bib-0028"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>H&#x000fc;cking</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kostic</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Pox</surname>
<given-names>C</given-names></string-name>, et al. <article-title>&#x003b1;&#x02010;Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon&#x02010;like peptide 1 (7&#x02010;36 amide) and to delay gastric emptying in Type&#x000a0;2 diabetic patients</article-title>. <source>Diabet Med</source><year>2005</year>; <volume>22</volume>: <fpage>470</fpage>&#x02013;<lpage>476</lpage><pub-id pub-id-type="pmid">15787675</pub-id></mixed-citation></ref></ref-list></back></article>